| |
Registration is now open for MASS West 2023! This is your opportunity to come together with medical affairs, field medical, and medical communications teams to share best practices, gain actionable insights, and crowdsource ideas to unique challenges. Click here to register today.
|
|
| By Annalee Armstrong Fifty-eight pounds. That’s how much weight patients lost on average at the end of 48 weeks when taking Eli Lilly’s next-generation obesity treatment. Twenty four percent of their body weight. |
|
|
|
By Ayla Ellison The Fierce 50 is a groundbreaking project that shines a spotlight on the true powerhouses driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. |
By Joseph Keenan The FDA recently hit two small U.S. manufacturing companies with separate warning letters that cited lax testing and operational procedures at each of their production locations. |
By Kevin Dunleavy For the first time in a decade, compensation for chief executives at S&P 500 companies declined in 2022. But you won’t find any evidence of the slide in biopharma. In an industry often said to be immune to economic headwinds, its top execs were again well compensated, with most getting significant bumps in pay |
|
Wednesday, July 12, 2023 | 2pm ET / 11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now.
|
|
By Zoey Becker In a surprise decision, the FDA issued powerhouse Eylea's high-dose version a complete response letter. But the company said it has nothing to do with the drug's efficacy or safety. |
By Max Bayer,Gabrielle Masson The Inflation Reduction Act's drug pricing reforms have sent shock waves through the drug development world, with executives arguing the legislation stands to stymie the development of innovative new medicines. |
By Fraiser Kansteiner To support production of VX-880 and a second clinical candidate for Type 1 diabetes, VX-264, Vertex and Lonza are teaming up on process development and scale-up for the manufacturing of the drugmaker’s portfolio of stem cell-derived, fully differentiated insulin-producing islet cell therapies. |
By Fraiser Kansteiner Eli Lilly will pay out $2.4 million as part of a settlement agreement with the U.S. Equal Employment Opportunity Commission, which sued the company in September over claims it had changed its hiring preferences in 2017 to prioritize recruitment of more millennials to its workforce. |
By Angus Liu Despite the controversy surrounding a relationship with departing director Alex Denner, Susan Langer has secured enough investor support to join Biogen’s board. |
By Fraiser Kansteiner Late last week, the FDA gave a green light to Pfizer’s once daily oral JAK inhibitor ritlecitinib—now christened Litfulo—in adults and children ages 12 and over with severe alopecia areata. Lilly’s rival JAK Olumiant, which became the first med the FDA specifically approved for alopecia in June 2022, is only cleared for use in adults. |
By Andrea Park Just a couple of months after laying out a plan to shave off at least $100 million from its 2023 expenses, Illumina is beginning to make those cost-cutting moves. |
By Angus Liu After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder. |
By Nick Paul Taylor An FDA advisory committee voted 10 to four in favor of Ipsen’s rare disease drug palovarotene despite members of the panel expressing significant concerns with the data. The vote boosts the prospects of the French drugmaker finally starting to deliver a return on its $1 billion bet on the drug candidate. |
By Nick Paul Taylor Pfizer is dropping one of its oral obesity drug candidates after seeing elevated liver enzymes in clinical trials. The setback leaves the Big Pharma’s near-term prospects resting on a candidate that is given twice as often as rival weight loss medicines in development at Eli Lilly and Novo Nordisk. |
By Andrea Park Abbott unveiled a new partnership with the American Diabetes Association and kicked off its previously announced WeightWatchers collaboration during the ADA’s annual scientific sessions in San Diego on Saturday. |
|
Wednesday, July 12, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperModern software development and its impact on addressing clinical trial complexity. Sponsored by: YPrime |
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive SummaryTraditional real-world data isn’t truly from the real world – it’s from the clinical world, and it’s missing a big part of neuro patients’ stories. Sponsored by: Evidation Health |
| WhitepaperBuilding a Sustainable Blueprint for a Holistic Market Access Strategy Sponsored by: EVERSANA® |
| |
|
